<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27911869</article-id><article-id pub-id-type="pmc">5444759</article-id><article-id pub-id-type="publisher-id">13721</article-id><article-id pub-id-type="doi">10.18632/oncotarget.13721</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research Paper</subject></subj-group></article-categories><title-group><article-title>Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Dai</surname><given-names>Xichao</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Xizhi</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Chaomin</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Jingting</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Changping</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of Oncology, Subei Peoples Hospital of Jiangsu Province, Clinical Medical College of Yangzhou University, Jiangsu, Yangzhou, China</aff><aff id="A2"><sup>2</sup> Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Suzhou, China</aff><aff id="A3"><sup>3</sup> Department of Oncology, The Third Affiliated Hospital of Soochow University, Suzhou, China</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>ChaominWang,</italic><email>zlydxc@163.com</email></corresp></author-notes><pub-date pub-type="collection"><day>2</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>30</day><month>11</month><year>2016</year></pub-date><volume>8</volume><issue>18</issue><fpage>30495</fpage><lpage>30501</lpage><history><date date-type="received"><day>13</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>19</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Dai et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link> (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><sec><title>Aims and background</title><p>This study was designed to compare the efficacy and safety of paclitaxel/oxaliplatin/fluorouracil (TOF) regimen and S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer (GC) patients.</p></sec><sec><title>Methods</title><p>Sixty patients were divided into TOF group and SOX groups randomly. Patients in the TOF group received paclitaxel (135 mg/m<sup>2</sup> iv) on day 1, oxaliplatin (100 mg/m<sup>2</sup> iv) on day 1, fluorouracil (500 mg/m<sup>2</sup> continuous iv) on day 1-5. The patients in the SOX group received oxaliplatin (130 mg/m<sup>2</sup> iv) on day 1 and S-1 (40 mg~60mg orally twice/day based on body surface area) on days 1-14. All the treatments were repeated every 21d for 4-6 cycles.</p></sec><sec><title>Results</title><p>The ORR and DCR of TOF group was 43.3% and 60.0%, respectively while that of SOX group was 36.7% and 56.7%. There were no statistical differences between the ORRs (?<sup>2</sup> = 0.278) and the DCRs (?<sup>2</sup> = 0.069) of the 2 groups. The majority of adverse events of two groups were hematological and digestive ones. Most of them were grade I and II. The adverse event rate of TOF group was higher than SOX group. The PFS times of TOF and SOX groups were 6.5 and 5.8 months, respectively. There was no statistical difference between the PFSs of the 2 groups (<italic>P</italic> = 0.451).</p></sec><sec><title>Conclusions</title><p>The efficacies of TOF and SOX regimens are similar but the safety of SOX regimen better than TOF regimen.</p></sec></abstract><kwd-group><kwd>paclitaxel</kwd><kwd>oxaliplatin</kwd><kwd>fluorouracil</kwd><kwd>S-1</kwd><kwd>metastatic gastric cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Gastric cancer occupies the second place of deaths caused by malignances over the world and It is especially popular in Asia [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref>],which is the third common carcinoma in China [<xref rid="R4" ref-type="bibr">4</xref>]. and the incidence rate and death rate of gastric cancer in Jiangsu Province are especially higher than the national average [<xref rid="R5" ref-type="bibr">5</xref>].</p><p>Surgical resection is the preferred treatment for gastric cancer, but approximately two-thirds of patients have metastatic disease at the time of diagnosis [<xref rid="R6" ref-type="bibr">6</xref>]. Prognosis in these patients is adverse. Median survival time of them is 3 to 5 months without treatment [<xref rid="R7" ref-type="bibr">7</xref>] while 5-year survival rate is reported as 9.4% [<xref rid="R8" ref-type="bibr">8</xref>]. Local recurrence and distant metastasis occur in 60% of mGC patients even with a radical stomach surgery [<xref rid="R9" ref-type="bibr">9</xref>]</p><p>Chemotherapy is the most effective treatment option for patients with advanced gastric cancer who can&#x02019;t be operated on [<xref rid="R10" ref-type="bibr">10</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref>] and the efficacy of postoperative chemotherapy has been acknowledged [<xref rid="R13" ref-type="bibr">13</xref>]. However, a worldwide consensus on standard chemotherapy regimens has yet to be established. The prognosis has gradually improved because of advances in chemotherapy regimens, but is not yet satisfactory.</p><p>Among various regimens, the combinations of paclitaxel/oxaliplatin/fluorouracil (TOF) regimen and S-1/oxaliplatin (SOX) regimen have become two important ones.</p><p>. As we all knew,the combination of Docetaxel /cisplation/ fluorouracil (DCF) had been verified by V325 trail to have higher RR, TTP, OS than FP4W [<xref rid="R14" ref-type="bibr">14</xref>].</p><p>Oxaliplatin is the third generation of diaminocyclohexane platinum compounds with broad spectrum antitumor activity, which is better safety than cisplatin [<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R15" ref-type="bibr">15</xref>]. Paclitaxel is another Taxanes besides Docetaxel which can induce hyperstabilization of microtubules resulting in cell cycle arrest and apoptosis [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>]. The objective response rate of patients with gastric cancer to paclitaxel is 20%-25% [<xref rid="R18" ref-type="bibr">18</xref>]. So We assumpt that the combination of paclitaxel/oxaliplatin/fluorouracil (TOF) regimen may substitute for DOF with lower toxicity.</p><p>S-1 is an oral anti-cancer drug of modified Fluorouracil composed of oteracil potassium, 5-chloro-2,4-dihydroxypy-ridine, tegafur [<xref rid="R19" ref-type="bibr">19</xref>],. which was also demonstrated to be not inferior to intravenous infusion of 5-FU when both were administered as a single drug [<xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref>]. Combination of cisplatin with S-1(CS) is considered as standard first-line chemotherapy regimen for metastatic gastric cancer by SPIRIT trail in Japan [<xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R22" ref-type="bibr">22</xref>].</p><p>The applying of S-1 as adjuvant chemotherapy for mGC can improve the overall survival (OS) and relapse-free survival [<xref rid="R23" ref-type="bibr">23</xref>].</p><p>OS in mGC was proven to benefit from S-1 based chemotherapy rather than 5-FU-based chemotherapy in a metal-analysis [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R24" ref-type="bibr">24</xref>]. Combination of S-1 with oxaliplatin(SOX) was demonstrated not to inferior to S1 plus cisplatin(CS) in PFS. SOX regimen also had well tolerance in patients with mGC [<xref rid="R25" ref-type="bibr">25</xref>]. From this, SOX is thought as a new first-line treatment choice of mGC in Asia, especially in China and Japan [<xref rid="R21" ref-type="bibr">21</xref>].</p><p>But, What is the activity of combinations of paclitaxel/oxaliplatin/fluorouracil (TOF) regimen in mGC ?</p><p>It is well known that only one regimen is optimal at one time. UP to now,There is no study comparing efficacy and safety of SOX. and TOF. So, This randomized and controlled study was performed to compare efficacy and safety of two regimen in mGC patients.</p></sec><sec sec-type="methods" id="s2"><title>PATIENTS AND METHODS</title><sec id="s2_1"><title>Patients</title><p>This study was approved by the ethics committees of all participating medical institutions and conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines. Between Feb. 2012 and Jan. 2014, a total of 60 patients bearing mGC were enrolled. All patients gave their written informed consent before enrollment.</p><p>The inclusion criteria were 1) pathologically confirmed mGC (stage IV), 2) ages between 20 and 80 years, 3) measurable or assessable lesions by imaging studies according to the RECIST guideline [<xref rid="R26" ref-type="bibr">26</xref>], 4) no prior chemotherapy except for postoperative adjuvant chemotherapy for more than 12 months before entry into the study, 5) Eastern Cooperative Oncology Group (ECOG) performance status score less than 3, 6) hepatic function (total bilirubin &#x02264; 1.5 &#x000d7; the institutional upper limit of normal value, aspartate aminotransferase/alanine aminotransferase &#x02264; 2.5 &#x000d7; the institutional upper limit of normal value, and alkaline phosphatase &#x02264; 2.5 &#x000d7; the institutional upper limit of normal value), renal function (serum creatinine level &#x02264; 1.5 mg/dL and creatinine clearance &#x02265; 50 ml/min) and adequate bone marrow function (hemoglobin level &#x02265; 90 g/L, white blood cell count of 4-10&#x000d7;10<sup>9</sup>/L, neutrophil count &#x02265; 2&#x000d7;10<sup>9</sup>/L, and platelet count &#x02265; 100&#x000d7;10<sup>9</sup>/L), and 7) estimated life expectancy more than 3 months and 8) no other secondary malignant tumors.</p><p>The exclusion criteria were 1) preexisted peripheral toxicity &#x02265; grade 2 of the National Cancer Institute Common Toxicity Criteria, 2) concurrent or prior malignancy, 3) central nervous system metastases, 4) concurrent treatment that interfered with the study evaluation, 5) active infection, 6) other uncontrolled underlying medical conditions that would impair the ability of the patients to receive the planned treatment, 7) having inadequate calorie and fluid intake, and 8) pregnant, and breastfeeding women or women of child-bearing potential without adequate contraception.</p></sec><sec id="s2_2"><title>Treatment</title><p>The patients were divided into TOF group and SOX groups randomly. Patients in the TOF group received paclitaxel (135 mg/m<sup>2</sup> iv) on day 1, oxaliplatin (100 mg/m<sup>2</sup> iv) on day 1, fluorouracil (500 mg/m<sup>2</sup> continuous iv) on day 1-5. The patients in the SOX group received oxaliplatin (130 mg/m<sup>2</sup> iv) on day 1 and S-1 (40 mg twice/day for body surface area &#x0003c; 1.25 m<sup>2</sup> and 60 mg twice/day for body surface area between 1.25 and 1.50 m<sup>2</sup> orally) on days 1-14. All the treatments were repeated every 21 d for 4-6 cycles.</p><p>The dose was modified based on the hematologic parameters and the degree of non-hematologic toxicities. The dose was modified for the TOF group as following, 1) if the hepatotoxicity reached grade 2 or more, the dose of paclitaxel for the following treatment was reduced to 100 mg/m<sup>2</sup> on days 1; if the hepatotoxicity was grade 3/4, the study was discontinued. (2) If the bone marrow suppression reached grade 4, the dose of paclitaxel for the following cycle was reduced to 100 mg/m<sup>2</sup> on day 1; if the bone marrow suppression reached grade 4, the study was discontinued; 3) if the mucositis reached grade 3/4, fluorouracil was administered from the next cycle for only 3 days; 4) if the creatinine clearance rate decreased to 30-50 mL/min resulted by the nephrotoxicity, the dose of oxaliplatin was reduced by 50%; if the creatinine clearance rate was lower than 30 mL/min, the study was discontinued.</p><p>The dose was modified for the SOX group as following: 1) if the neurotoxic toxicity was grade 1/2, the dose of oxaliplatin was reduced by 25%; 2) if the neurotoxic toxicity was grade 3/4 or persistent, the oxaliplatin was omitted from the regimen until the neurotoxic toxicity was resolved to grade 1 or better.</p></sec><sec id="s2_3"><title>Evaluation</title><p>The outcomes of electrocardiogram, computed tomography (CT) scan, and levels of tumor markers (CA19-9, CA72-4, CA24-2 and carcinoembryonic antigen) were obtained from the patients within 7 d after enrollment. Hematology tests, biochemistry tests, and assessment of symptoms and signs were carried out for the patients within 3 days before enrollment and every week during the study period. CT scans were carried out and levels of tumor markers were measured before each cycle. According to the RECIST guideline [<xref rid="R16" ref-type="bibr">16</xref>], responses concluded complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). To confirm the PR or CR, the levels of tumor markers were measured no less than 4 weeks after the objective response was obtained. Responses were assessed by the independent review committee. The overall response rate (ORR) was defined as the sum of CR and PR rates. The disease controlled rate (DCR) was defined as the sum of CR, PR and SD rates. Safety was evaluated according to the NCI-CTC. PFS is defined as the time from randomization until objective tumor progression or death.</p><p>PFS is primary endpoint of our study. The secondary endpoint is ORR, DCR.</p></sec><sec id="s2_4"><title>Statistical analysis</title><p>Statistical analysis was performed with the SPSS software (version 17.0, SPSS). Chi-square test was used to compare the categorical data. <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec id="s3"><title>RESULTS</title><sec id="s3_1"><title>Patient baseline characteristics</title><p>The patient baseline characteristics are listed in Table <xref ref-type="table" rid="T1">1</xref>. The difference between two groups was not statistically significant in any characteristics.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Patients baseline characteristics (<italic>n</italic> = 60)</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">Characteristics</th><th colspan="2" align="left" valign="middle" rowspan="1">Patients (%)</th><th rowspan="2" align="left" valign="middle" colspan="1"><italic>P</italic></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">TOF (<italic>n</italic>= 30)</th><th align="left" valign="middle" rowspan="1" colspan="1">SOX (<italic>n</italic>= 30)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">0.785</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female</td><td align="left" valign="middle" rowspan="1" colspan="1">9</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td rowspan="2" align="left" valign="middle" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male</td><td align="left" valign="middle" rowspan="1" colspan="1">21</td><td align="left" valign="middle" rowspan="1" colspan="1">19</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">0.787</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Median</td><td align="left" valign="middle" rowspan="1" colspan="1">58</td><td align="left" valign="middle" rowspan="1" colspan="1">57</td><td rowspan="2" align="left" valign="middle" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Range</td><td align="left" valign="middle" rowspan="1" colspan="1">21-73</td><td align="left" valign="middle" rowspan="1" colspan="1">20-75</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Histologic type</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">0.757</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Adenocarcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">22</td><td align="left" valign="middle" rowspan="1" colspan="1">21</td><td rowspan="3" align="left" valign="middle" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Adenosquamous carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">5</td><td align="left" valign="middle" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mucinous carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">3</td><td align="left" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No. of metastatic lesion</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">0.771</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0-1</td><td align="left" valign="middle" rowspan="1" colspan="1">7</td><td align="left" valign="middle" rowspan="1" colspan="1">9</td><td rowspan="2" align="left" valign="middle" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265; 2</td><td align="left" valign="middle" rowspan="1" colspan="1">23</td><td align="left" valign="middle" rowspan="1" colspan="1">21</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Prior adjuvant chemotherapy</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="left" valign="middle" rowspan="1" colspan="1">18</td><td align="left" valign="middle" rowspan="1" colspan="1">18</td><td rowspan="2" align="left" valign="middle" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="left" valign="middle" rowspan="1" colspan="1">12</td><td align="left" valign="middle" rowspan="1" colspan="1">12</td></tr></tbody></table></table-wrap></sec><sec id="s3_2"><title>ORR and DCR</title><p>The patients all received 4-6 cycles of chemotherapy and were suitable for response evaluation.</p><p>No patients developed severe adverse events leading to exclusion of the efficacy analysis.</p><p>Among the patients in TOF group, 1 achieved a CR, 12 achieved a PR, 5 achieved a SD, and 12 achieved a PD, with an ORR of 43.3% and a DCR of 60.0%.</p><p>Among the patients in SOX group, 1 achieved a CR, 10 achieved a PR, 6 achieved a SD, and 13 achieved a PD, with an ORR of 36.7% and a DCR of 56.7%. There were no statistical differences between the ORRs (&#x003c7;<sup>2</sup> = 0.278) and the DCRs (&#x003c7;<sup>2</sup> = 0.069) of the 2 groups. See Table <xref ref-type="table" rid="T2">2</xref>.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Objective response of TOF and SOX groups, <italic>n</italic> (%)</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" rowspan="1" colspan="1">CR</th><th align="center" valign="middle" rowspan="1" colspan="1">PR</th><th align="center" valign="middle" rowspan="1" colspan="1">SD</th><th align="center" valign="middle" rowspan="1" colspan="1">PD</th><th colspan="2" align="center" valign="middle" rowspan="1">ORR</th><th colspan="2" align="center" valign="middle" rowspan="1">DCR</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">TOF (<italic>n</italic> =30)</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (3.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">12 (40.0)</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (16.7)</td><td align="left" valign="middle" rowspan="1" colspan="1">12 (40.0)</td><td align="left" valign="middle" rowspan="1" colspan="1">24 (80.0)</td><td rowspan="2" align="left" valign="middle" colspan="1"><italic>P</italic> = 0.243 &#x003c7;2 = 1.367</td><td align="left" valign="middle" rowspan="1" colspan="1">18 (60.0)</td><td rowspan="2" align="left" valign="middle" colspan="1"><italic>P</italic> = 0.793<break/>&#x003c7;2 = 0.069</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SOX (<italic>n</italic> =30)</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (3.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">10 (33.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">6 (20.0)</td><td align="left" valign="middle" rowspan="1" colspan="1">13 (43.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">20 (66.7)</td><td align="left" valign="middle" rowspan="1" colspan="1">17 (56.7)</td></tr></tbody></table></table-wrap><p>In TOF group, the efficacy of the 1 patient was evaluated as CR, 12 patients was evaluated as PR. 5 patients was evaluated as SD, 12 patients was evaluated as PD. The ORR was 43.3% with a DCR of 60.0%. In SOX group, the efficacy of the 1 patient was evaluated as CR, 10 patients was evaluated as PR. 6 patients was evaluated as SD, 13 patients was evaluated as PD. The ORR was 36.7%, with a DCR of 56.7%. There were no statistical differences between the ORRs (&#x003c7;<sup>2</sup> = 0.278) and the DCRs (&#x003c7;<sup>2</sup> = 0.069) of the 2 groups. See Table <xref ref-type="table" rid="T2">2</xref>.</p></sec><sec id="s3_3"><title>Safety</title><p>No patient discontinued or ended the treatment due to intolerable adverse events. The majority of adverse events of both the 2 groups were hematological and digestive ones. Most of them were grade I and II and grade III and IV hematological adverse events were also observed. Generally, the adverse event rate of TOF group was higher than SOX group. There were no statistical differences between the grade III and IV adverse events the 2 groups. And basically the adverse events relieved after symptomatic treatment. See Table <xref ref-type="table" rid="T3">3</xref>.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Adverse events of TOF and SOX groups, <italic>n</italic> (%)</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="center" valign="middle" colspan="1">Toxicity</th><th colspan="2" align="center" valign="middle" rowspan="1">TOF</th><th colspan="2" align="center" valign="middle" rowspan="1">SOX</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">I - II</th><th align="center" valign="middle" rowspan="1" colspan="1">III - IV</th><th align="center" valign="middle" rowspan="1" colspan="1">I - II</th><th align="center" valign="middle" rowspan="1" colspan="1">III - IV</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">WBC decreasing</td><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Neutrophil decreasing</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Anemia</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLT decreasing</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diarrhea</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vomiting</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Alopecia</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Oral mucositis</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hand-foot syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Neurotoxicity</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><p>WBC: white blood cell; PLT: platelet</p></table-wrap-foot></table-wrap></sec><sec id="s3_4"><title>Progression free survival (PFS)</title><p>The PFS times of TOF and SOX groups were 6.5 and 5.8 months, respectively. There is no statistical difference between the PFSs of the 2 groups (<italic>P</italic> = 0.451). See Figure <xref ref-type="fig" rid="F1">1</xref>.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>The progression free survival curves of the TOF and SOX groups</title><p>There is no statistical difference between the progression free survival times of the 2 groups.</p></caption><graphic xlink:href="oncotarget-08-30495-g001"/></fig></sec></sec><sec id="s4"><title>DISCUSSION</title><p>Chinese gastric cancer patients are oftern diagnosed at later stage with distant metastases [<xref rid="R27" ref-type="bibr">27</xref>] Although there are many treatment modality such as operation combined with chemotherapy which can be used to treat gastric cancer [<xref rid="R28" ref-type="bibr">28</xref>, <xref rid="R29" ref-type="bibr">29</xref>], there is currently no standard regimen for mGC patients. Therefore, it is urgent to obtain a new therapeutic strategy with better efficacy and tolerable toxicity. In the present study, SOX regimen is usually considered to be the first-line therapy choice for mGC in China [<xref rid="R30" ref-type="bibr">30</xref>] and Japan [<xref rid="R31" ref-type="bibr">31</xref>] TOF regimen is not that widely applied. V325 trail has proven the ORR(36.7%), TTP(5.6m) of DCF regimen, docetaxel/cisplatin/ fluorouracil, higher than FP4w [<xref rid="R14" ref-type="bibr">14</xref>]. It can be chose as first-line regimen for mGC but for high toxicity.</p><p>Following promising phase II study results [<xref rid="R32" ref-type="bibr">32</xref>], [<xref rid="R33" ref-type="bibr">33</xref>, <xref rid="R34" ref-type="bibr">34</xref>], oxaliplatin was verified to have the non-inferiority compared with cisplatin with low toxicity. As we all know Paclitaxel is another taxane which has been used widely in mGC.</p><p>So We assumpted that TOF may substitute for DCF with tolerable side effect.</p><p>The efficacy and safety of TOF and SOX regimen were discovered in mGC. We found that the therapeutic efficacies of the 2 groups were similar but SOX regimen seemed to have lower toxicity than TOF regimen.</p><p>Different combination chemotherapy regimens as first-line therapy demonstrated median PFS of 5-6 months and response rate of 35-45% [<xref rid="R35" ref-type="bibr">35</xref>].</p><p>Our data on antitumor response basically meet with this range and we gained a slightly longer PFS.</p><p>There are few articles focusing on TOF in mGC, which is possible due to the consideration of the adverse events of this regimen. Actually our results do confirm this consideration.</p><p>We did not report the outcome of overall survival of the patients due to the 5-year follow-up has not been finished. And there is no statistical difference between Progression free survival times of the 2 groups. However, we can still find the tendency of longer survival time of TOF regimen. The survival outcome needs to be clarified by studies with larger sample sizes.</p><p>Several recent clinical trails have shown that SOX regimen is a effective and easily tolerated treatment method for mGC patients [<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R37" ref-type="bibr">37</xref>].</p><p>The response rates of SOX for mGC range from 53.7% to 59.0% [<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R38" ref-type="bibr">38</xref>]. Besides, Koizumi et al. [<xref rid="R31" ref-type="bibr">31</xref>] reported the median PFS time of patients receiving SOX regimen was 6.5 months and the incidence of grade 3/4 toxicity was lower. Similarly, Oh et al. [<xref rid="R37" ref-type="bibr">37</xref>] and Liu et al. [<xref rid="R30" ref-type="bibr">30</xref>] also showed that the SOX regimen was easily tolerated and more convenient treatment as a first-line therapy for mGC patients. All these results met ours.</p><p>Moreover, the development of adverse events had worse outcomes than the patients who did not experience adverse events, suggesting that the frequency of adverse events is an important factor in evaluating the efficacy of the drug [<xref rid="R39" ref-type="bibr">39</xref>].</p><p>Conclusively, we demonstrated that the therapeutic efficacies of TOF regimen and SOX regimen are similar but the safety of SOX regimen is more tolerable than TOF regimen. Hence, we would rather recommend SOX regimen for mGC patients not only because of the acceptable benefits to the efficacy and PFS but more importantly the better safety. Further studies are guaranteed to corroborate the result of this study.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>There is no conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2014</article-title><source>CA Cancer J Clin</source><year>2014</year><volume>64</volume><fpage>9</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.3322/caac.21208</pub-id><pub-id pub-id-type="pmid">24399786</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamangar</surname><given-names>F</given-names></name><name><surname>Dores</surname><given-names>GM</given-names></name><name><surname>Anderson</surname><given-names>WF</given-names></name></person-group><article-title>Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>2137</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.05.2308</pub-id><pub-id pub-id-type="pmid">16682732</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>MM</given-names></name><name><surname>Wu</surname><given-names>WJ</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><name><surname>Zhang</surname><given-names>DS</given-names></name><name><surname>Luo</surname><given-names>HY</given-names></name><name><surname>Qiu</surname><given-names>MZ</given-names></name><name><surname>Wang</surname><given-names>FH</given-names></name><name><surname>Ren</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>ZL</given-names></name><name><surname>Xu</surname><given-names>RH</given-names></name></person-group><article-title>S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e82798</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0082798</pub-id><pub-id pub-id-type="pmid">24349363</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>N</given-names></name></person-group><article-title>Cancer trends in China</article-title><source>Jpn J Clin Oncol</source><year>2010</year><volume>40</volume><fpage>281</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyp187</pub-id><pub-id pub-id-type="pmid">20085904</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>G</given-names></name><name><surname>Pu</surname><given-names>Y</given-names></name></person-group><article-title>Analysis and estimates of the attributable risk for environmental and genetic risk factors in gastric cancer in a Chinese population</article-title><source>J Toxicol Environ Health A</source><year>2009</year><volume>72</volume><fpage>759</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">19492240</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanhoefer</surname><given-names>U</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Ducreux</surname><given-names>MP</given-names></name><name><surname>Lacave</surname><given-names>AJ</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Planker</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>JG</given-names></name><name><surname>Piedbois</surname><given-names>P</given-names></name><name><surname>Paillot</surname><given-names>B</given-names></name><name><surname>Bodenstein</surname><given-names>H</given-names></name><name><surname>Schmoll</surname><given-names>HJ</given-names></name><name><surname>Bleiberg</surname><given-names>H</given-names></name><etal/></person-group><article-title>Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2648</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">10894863</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Ekstrom</surname><given-names>K</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Sjoden</surname><given-names>PO</given-names></name><name><surname>Haglund</surname><given-names>U</given-names></name><name><surname>Svensson</surname><given-names>C</given-names></name><name><surname>Enander</surname><given-names>LK</given-names></name><name><surname>Linne</surname><given-names>T</given-names></name><name><surname>Sellstrom</surname><given-names>H</given-names></name><name><surname>Heuman</surname><given-names>R</given-names></name></person-group><article-title>Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer</article-title><source>Ann Oncol</source><year>1997</year><volume>8</volume><fpage>163</fpage><lpage>8</lpage></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamura</surname><given-names>Y</given-names></name><name><surname>Yoshimi</surname><given-names>I</given-names></name></person-group><article-title>Comparison of Cancer Mortality (Stomach Cancer) in Five Countries: France, Italy, Japan, UK and USA from the WHO Mortality Database (1960-2000)</article-title><source>Jpn J Clin Oncol</source><year>2005</year><volume>35</volume><fpage>103</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyi030</pub-id><pub-id pub-id-type="pmid">15709097</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>F</given-names></name><name><surname>Vega-Villegas</surname><given-names>ME</given-names></name><name><surname>Lopez-Brea</surname><given-names>MF</given-names></name></person-group><article-title>Chemotherapy of advanced gastric cancer</article-title><source>Cancer Treat Rev</source><year>2007</year><volume>33</volume><fpage>315</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2007.01.004</pub-id><pub-id pub-id-type="pmid">17376598</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>AD</given-names></name><name><surname>Grothe</surname><given-names>W</given-names></name><name><surname>Haerting</surname><given-names>J</given-names></name><name><surname>Kleber</surname><given-names>G</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Fleig</surname><given-names>WE</given-names></name></person-group><article-title>Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>2903</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/jco.2005.05.0245</pub-id><pub-id pub-id-type="pmid">16782930</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murad</surname><given-names>AM</given-names></name><name><surname>Santiago</surname><given-names>FF</given-names></name><name><surname>Petroianu</surname><given-names>A</given-names></name><name><surname>Rocha</surname><given-names>PR</given-names></name><name><surname>Rodrigues</surname><given-names>MA</given-names></name><name><surname>Rausch</surname><given-names>M</given-names></name></person-group><article-title>Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer</article-title><source>Cancer</source><year>1993</year><volume>72</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">8508427</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Kebinu</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Ayixiamu Mayier</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>P</given-names></name><name><surname>Naman</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer</article-title><source>Onco Targets Ther</source><year>2013</year><volume>6</volume><fpage>925</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2147/ott.s46487</pub-id><pub-id pub-id-type="pmid">23926435</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Francesco</surname><given-names>AM</given-names></name><name><surname>Ruggiero</surname><given-names>A</given-names></name><name><surname>Riccardi</surname><given-names>R</given-names></name></person-group><article-title>Cellular and molecular aspects of drugs of the future: oxaliplatin</article-title><source>Cell Mol Life Sci</source><year>2002</year><volume>59</volume><fpage>1914</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">12530522</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Moiseyenko</surname><given-names>VM</given-names></name><name><surname>Tjulandin</surname><given-names>S</given-names></name><name><surname>Majlis</surname><given-names>A</given-names></name><name><surname>Constenla</surname><given-names>M</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Fodor</surname><given-names>M</given-names></name><name><surname>Chao</surname><given-names>Y</given-names></name><name><surname>Voznyi</surname><given-names>E</given-names></name><name><surname>Marabotti</surname><given-names>C</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name></person-group><article-title>Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>3205</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/jco.2006.10.4968</pub-id><pub-id pub-id-type="pmid">17664467</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriguchi</surname><given-names>M</given-names></name><name><surname>Nonaka</surname><given-names>Y</given-names></name><name><surname>Yanagie</surname><given-names>H</given-names></name><name><surname>Yoshizaki</surname><given-names>I</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><name><surname>Sekiguchi</surname><given-names>M</given-names></name></person-group><article-title>A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines</article-title><source>Biomed Pharmacother</source><year>2003</year><volume>57</volume><fpage>412</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">14652166</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiff</surname><given-names>PB</given-names></name><name><surname>Fant</surname><given-names>J</given-names></name><name><surname>Horwitz</surname><given-names>SB</given-names></name></person-group><article-title>Promotion of microtubule assembly <italic>in vitro</italic> by taxol</article-title><source>Nature</source><year>1979</year><volume>277</volume><fpage>665</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">423966</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganansia-Leymarie</surname><given-names>V</given-names></name><name><surname>Bischoff</surname><given-names>P</given-names></name><name><surname>Bergerat</surname><given-names>JP</given-names></name><name><surname>Holl</surname><given-names>V</given-names></name></person-group><article-title>Signal transduction pathways of taxanes-induced apoptosis</article-title><source>Curr Med Chem Anticancer Agents</source><year>2003</year><volume>3</volume><fpage>291</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">12769774</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name><name><surname>Brienza</surname><given-names>S</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Metzger</surname><given-names>G</given-names></name><name><surname>Itzakhi</surname><given-names>M</given-names></name><name><surname>Caussanel</surname><given-names>JP</given-names></name><name><surname>Kunstlinger</surname><given-names>F</given-names></name><name><surname>Lecouturier</surname><given-names>S</given-names></name><name><surname>Descorps-Declere</surname><given-names>A</given-names></name><name><surname>Jasmin</surname><given-names>C</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Reinberg</surname><given-names>A</given-names></name></person-group><article-title>A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer</article-title><source>Cancer</source><year>1992</year><volume>69</volume><fpage>893</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">1735081</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirasaka</surname><given-names>T</given-names></name><name><surname>Shimamato</surname><given-names>Y</given-names></name><name><surname>Ohshimo</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Yonekura</surname><given-names>K</given-names></name><name><surname>Fukushima</surname><given-names>M</given-names></name></person-group><article-title>Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators</article-title><source>Anticancer Drugs</source><year>1996</year><volume>7</volume><fpage>548</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">8862723</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boku</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Fukuda</surname><given-names>H</given-names></name><name><surname>Shirao</surname><given-names>K</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Sawaki</surname><given-names>A</given-names></name><name><surname>Koizumi</surname><given-names>W</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Takiuchi</surname><given-names>H</given-names></name><name><surname>Nasu</surname><given-names>J</given-names></name><name><surname>Ohtsu</surname><given-names>A</given-names></name></person-group><article-title>Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>1063</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/s1470-2045(09)70259-1</pub-id><pub-id pub-id-type="pmid">19818685</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lordick</surname><given-names>F</given-names></name><name><surname>Lorenzen</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Ilson</surname><given-names>D</given-names></name></person-group><article-title>Optimal chemotherapy for advanced gastric cancer: is there a global consensus?</article-title><source>Gastric Cancer</source><year>2014</year><volume>17</volume><fpage>213</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/s10120-013-0297-z</pub-id><pub-id pub-id-type="pmid">24048758</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koizumi</surname><given-names>W</given-names></name><name><surname>Narahara</surname><given-names>H</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Takagane</surname><given-names>A</given-names></name><name><surname>Akiya</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>M</given-names></name><name><surname>Miyashita</surname><given-names>K</given-names></name><name><surname>Nishizaki</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>O</given-names></name><name><surname>Takiyama</surname><given-names>W</given-names></name><name><surname>Toh</surname><given-names>Y</given-names></name><name><surname>Nagaie</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>S</given-names></name><etal/></person-group><article-title>S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial</article-title><source>Lancet Oncol</source><year>2008</year><volume>9</volume><fpage>215</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/s1470-2045(08)70035-4</pub-id><pub-id pub-id-type="pmid">18282805</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasako</surname><given-names>M</given-names></name><name><surname>Sakuramoto</surname><given-names>S</given-names></name><name><surname>Katai</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>T</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Nashimoto</surname><given-names>A</given-names></name><name><surname>Fujii</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Ohashi</surname><given-names>Y</given-names></name></person-group><article-title>Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>4387</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1200/jco.2011.36.5908</pub-id><pub-id pub-id-type="pmid">22010012</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Liao</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name></person-group><article-title>S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis</article-title><source>Med Oncol</source><year>2011</year><volume>28</volume><fpage>1004</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/s12032-010-9594-0</pub-id><pub-id pub-id-type="pmid">20552300</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shu</surname><given-names>C</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name></person-group><article-title>Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer</article-title><source>Oncol Lett</source><year>2015</year><volume>9</volume><fpage>1451</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.3892/ol.2014.2821</pub-id><pub-id pub-id-type="pmid">25663930</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Wanders</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RS</given-names></name><name><surname>Rubinstein</surname><given-names>L</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Van Glabbeke</surname><given-names>M</given-names></name><name><surname>van Oosterom</surname><given-names>AT</given-names></name><name><surname>Christian</surname><given-names>MC</given-names></name><name><surname>Gwyther</surname><given-names>SG</given-names></name></person-group><article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>205</fpage><lpage>16</lpage></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>ZG</given-names></name><name><surname>Tao</surname><given-names>SF</given-names></name><name><surname>Lokesh</surname><given-names>G</given-names></name><name><surname>Peng</surname><given-names>SY</given-names></name></person-group><article-title>Surgical management of gastric stump cancer: a report of 37 cases</article-title><source>J Zhejiang Univ Sci B</source><year>2005</year><volume>6</volume><fpage>38</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1631/jzus.2005.B0038</pub-id><pub-id pub-id-type="pmid">15593390</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollmannsberger</surname><given-names>C</given-names></name><name><surname>Budach</surname><given-names>W</given-names></name><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>Schleucher</surname><given-names>N</given-names></name><name><surname>Hehr</surname><given-names>T</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Schleicher</surname><given-names>J</given-names></name><name><surname>Vanhoefer</surname><given-names>U</given-names></name><name><surname>Jehle</surname><given-names>EC</given-names></name><name><surname>Oechsle</surname><given-names>K</given-names></name><name><surname>Trarbach</surname><given-names>T</given-names></name><name><surname>Boehlke</surname><given-names>I</given-names></name><name><surname>Kanz</surname><given-names>L</given-names></name><etal/></person-group><article-title>Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><fpage>1326</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdi252</pub-id><pub-id pub-id-type="pmid">15919686</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>WL</given-names></name><name><surname>Li</surname><given-names>DG</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>HM</given-names></name></person-group><article-title>Clinical and experimental study of oxaliplatin in treating human gastric carcinoma</article-title><source>World J Gastroenterol</source><year>2004</year><volume>10</volume><fpage>2911</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15334700</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Ying</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name></person-group><article-title>S-1 combined with oxaliplatin as first line chemotherapy for Chinese advanced gastric cancer patients</article-title><source>Hepatogastroenterology</source><year>2012</year><volume>59</volume><fpage>649</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.5754/hge11893</pub-id><pub-id pub-id-type="pmid">22328264</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koizumi</surname><given-names>W</given-names></name><name><surname>Takiuchi</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Boku</surname><given-names>N</given-names></name><name><surname>Fuse</surname><given-names>N</given-names></name><name><surname>Muro</surname><given-names>K</given-names></name><name><surname>Komatsu</surname><given-names>Y</given-names></name><name><surname>Tsuburaya</surname><given-names>A</given-names></name></person-group><article-title>Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)</article-title><source>Ann Oncol</source><year>2010</year><volume>21</volume><fpage>1001</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdp464</pub-id><pub-id pub-id-type="pmid">19875759</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Tigaud</surname><given-names>JM</given-names></name><name><surname>Gamelin</surname><given-names>E</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Brunet</surname><given-names>R</given-names></name><name><surname>Francois</surname><given-names>E</given-names></name><name><surname>Jacob</surname><given-names>JH</given-names></name><name><surname>Levoir</surname><given-names>D</given-names></name><name><surname>Taamma</surname><given-names>A</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Cvitkovic</surname><given-names>E</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><article-title>Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>4543</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12454110</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Batran</surname><given-names>SE</given-names></name><name><surname>Atmaca</surname><given-names>A</given-names></name><name><surname>Hegewisch-Becker</surname><given-names>S</given-names></name><name><surname>Jaeger</surname><given-names>D</given-names></name><name><surname>Hahnfeld</surname><given-names>S</given-names></name><name><surname>Rummel</surname><given-names>MJ</given-names></name><name><surname>Seipelt</surname><given-names>G</given-names></name><name><surname>Rost</surname><given-names>A</given-names></name><name><surname>Orth</surname><given-names>J</given-names></name><name><surname>Knuth</surname><given-names>A</given-names></name><name><surname>Jaeger</surname><given-names>E</given-names></name></person-group><article-title>Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>658</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1200/jco.2004.07.042</pub-id><pub-id pub-id-type="pmid">14966088</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lordick</surname><given-names>F</given-names></name><name><surname>Lorenzen</surname><given-names>S</given-names></name><name><surname>Stollfuss</surname><given-names>J</given-names></name><name><surname>Vehling-Kaiser</surname><given-names>U</given-names></name><name><surname>Kullmann</surname><given-names>F</given-names></name><name><surname>Hentrich</surname><given-names>M</given-names></name><name><surname>Zumschlinge</surname><given-names>R</given-names></name><name><surname>Dietzfelbinger</surname><given-names>H</given-names></name><name><surname>Thoedtmann</surname><given-names>J</given-names></name><name><surname>Hennig</surname><given-names>M</given-names></name><name><surname>Seroneit</surname><given-names>T</given-names></name><name><surname>Bredenkamp</surname><given-names>R</given-names></name><name><surname>Duyster</surname><given-names>J</given-names></name><etal/></person-group><article-title>Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer</article-title><source>Br J Cancer</source><year>2005</year><volume>93</volume><fpage>190</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6602697</pub-id><pub-id pub-id-type="pmid">16012522</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name></person-group><article-title>S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil</article-title><source>Int J Clin Exp Pathol</source><year>2014</year><volume>7</volume><fpage>4274</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">25120809</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>GM</given-names></name><name><surname>Jeung</surname><given-names>HC</given-names></name><name><surname>Rha</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Jung</surname><given-names>I</given-names></name><name><surname>Nam</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name></person-group><article-title>A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer</article-title><source>Eur J Cancer</source><year>2012</year><volume>48</volume><fpage>518</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2011.12.017</pub-id><pub-id pub-id-type="pmid">22243774</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>SY</given-names></name><name><surname>Kwon</surname><given-names>HC</given-names></name><name><surname>Jeong</surname><given-names>SH</given-names></name><name><surname>Joo</surname><given-names>YT</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Cho</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>MH</given-names></name><name><surname>Go</surname><given-names>SI</given-names></name><name><surname>Lee</surname><given-names>GW</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>JH</given-names></name></person-group><article-title>A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer</article-title><source>Invest New Drugs</source><year>2012</year><volume>30</volume><fpage>350</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s10637-010-9507-2</pub-id><pub-id pub-id-type="pmid">20706861</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>JL</given-names></name><name><surname>Ryu</surname><given-names>MH</given-names></name><name><surname>Chang</surname><given-names>HM</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Sym</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Jang</surname><given-names>G</given-names></name><name><surname>Yoo</surname><given-names>C</given-names></name><name><surname>Bae</surname><given-names>KS</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name></person-group><article-title>Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2010</year><volume>65</volume><fpage>473</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/s00280-009-1052-3</pub-id><pub-id pub-id-type="pmid">19551382</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakuramoto</surname><given-names>S</given-names></name><name><surname>Sasako</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Kinoshita</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>M</given-names></name><name><surname>Nashimoto</surname><given-names>A</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Ohashi</surname><given-names>Y</given-names></name><name><surname>Imamura</surname><given-names>H</given-names></name><name><surname>Higashino</surname><given-names>M</given-names></name><name><surname>Yamamura</surname><given-names>Y</given-names></name><name><surname>Kurita</surname><given-names>A</given-names></name><etal/></person-group><article-title>Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>1810</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa072252</pub-id><pub-id pub-id-type="pmid">17978289</pub-id></element-citation></ref></ref-list></back></article>